Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.
Dr Nicholas Silvestri shares AAN 2025 highlights, including anticipated presentations, quick takeaways, and insights on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback